Last reviewed · How we verify

Clobetasol Ointment

National Institute of Allergy and Infectious Diseases (NIAID) · FDA-approved active Small molecule

Clobetasol Ointment is a Topical corticosteroid (Class I/super-potent) Small molecule drug developed by National Institute of Allergy and Infectious Diseases (NIAID). It is currently FDA-approved for Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Psoriasis, Eczema. Also known as: Clobex spray, Mucoadhesive Clobetasol Patch, Dermovate.

Clobetasol propionate is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors.

Clobetasol propionate is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors. Used for Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Psoriasis, Eczema.

At a glance

Generic nameClobetasol Ointment
Also known asClobex spray, Mucoadhesive Clobetasol Patch, Dermovate
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Drug classTopical corticosteroid (Class I/super-potent)
TargetGlucocorticoid receptor
ModalitySmall molecule
Therapeutic areaDermatology
PhaseFDA-approved

Mechanism of action

Clobetasol propionate is a Class I (super-potent) corticosteroid that works by activating intracellular glucocorticoid receptors, leading to decreased production of inflammatory mediators, reduced immune cell infiltration, and suppression of local inflammatory responses. It reduces erythema, pruritus, and other signs of skin inflammation through these anti-inflammatory and immunosuppressive mechanisms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Clobetasol Ointment

What is Clobetasol Ointment?

Clobetasol Ointment is a Topical corticosteroid (Class I/super-potent) drug developed by National Institute of Allergy and Infectious Diseases (NIAID), indicated for Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Psoriasis, Eczema.

How does Clobetasol Ointment work?

Clobetasol propionate is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors.

What is Clobetasol Ointment used for?

Clobetasol Ointment is indicated for Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Psoriasis, Eczema, Lichen planus, Vitiligo (adjunctive).

Who makes Clobetasol Ointment?

Clobetasol Ointment is developed and marketed by National Institute of Allergy and Infectious Diseases (NIAID) (see full National Institute of Allergy and Infectious Diseases (NIAID) pipeline at /company/national-institute-of-allergy-and-infectious-diseases-niaid).

Is Clobetasol Ointment also known as anything else?

Clobetasol Ointment is also known as Clobex spray, Mucoadhesive Clobetasol Patch, Dermovate.

What drug class is Clobetasol Ointment in?

Clobetasol Ointment belongs to the Topical corticosteroid (Class I/super-potent) class. See all Topical corticosteroid (Class I/super-potent) drugs at /class/topical-corticosteroid-class-i-super-potent.

What development phase is Clobetasol Ointment in?

Clobetasol Ointment is FDA-approved (marketed).

What are the side effects of Clobetasol Ointment?

Common side effects of Clobetasol Ointment include Skin atrophy, Striae, Telangiectasia, Folliculitis, Hypertrichosis, Acneiform eruptions.

What does Clobetasol Ointment target?

Clobetasol Ointment targets Glucocorticoid receptor and is a Topical corticosteroid (Class I/super-potent).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing